|Aclacinomycin A Topoisomerase I and II inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Description||Aclarubicin (aclacinomycin A), an anthracycline drug, specific inhibitor of the 20S proteasome chymotrypsin-like activity.|
|Cas No.||57576-44-0||SDF||Download SDF|
|Canonical SMILES||OC1=CC=CC(C(C2=C3C(O)=C4C([[email protected]@H](C(OC)=O)[[email protected]@](O)(CC)C[[email protected]@H]4O[[email protected]]5C[[email protected]](N(C)C)[[email protected]](O[[email protected]@H]6O[[email protected]@H](C)[[email protected]@H](O[[email protected]@H]7O[[email protected]@H](C)C(CC7)=O)[[email protected]@H](O)C6)[[email protected]](C)O5)=C2)=O)=C1C3=O|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
Aclacinomycin A is a dual inhibitor of topoisomerase I and II . Aclacinomycin A is an anticancer drug which can reduce the tumor with minimal damage to normal cells. Aclacinomycin A shows potency against a wide variety of solid tumours and haematological malignancies. In A549, HepG2 and MCF-7 cells, Aclacinomycin A shows cytotoxic activity with IC50 values of 0.27μM, 0.32μM and 0.62μM, respectively. Aclacinomycin A induces cell apoptosis in these cells and the effects change to be necrosis when the incubation time is prolonged. Aclacinomycin A is demonstrated to increase the activity of both caspase-3 and caspase-8, thus inducing the activation of PARP. Apart from that, as an inhibitor of opoisomerases, Aclacinomycin A is found to induce DNA damage in V79 and irs-2 cells. Aclacinomycin A is used to treat acute leukaemias, lymphomas and other solid tumors through its inhibition of topo II [1, 2].
 Hajji N, Mateos S, Pastor N, Domínguez I, Cortés F. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35. Rogalska A, Szwed M, Jó wiak Z. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res. 2010 Jul 19;700(1-2):1-10.